A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF Nab-PACLITAXEL (ABI-007) PLUS GEMCITABINE IN SUBJECTS WITH ADVANCED PANCREATIC CANCER WHO HAVE CHOLESTATIC HYPERBILIRUBINEMIA SECONDARY TO BILE DUCT OBSTRUCTION

Trial Profile

A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF Nab-PACLITAXEL (ABI-007) PLUS GEMCITABINE IN SUBJECTS WITH ADVANCED PANCREATIC CANCER WHO HAVE CHOLESTATIC HYPERBILIRUBINEMIA SECONDARY TO BILE DUCT OBSTRUCTION

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine
  • Indications Cholestasis; Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Mar 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Jan 2016 Planned end date changed from 1 Oct 2018 to 1 Feb 2016, as reported by ClinicalTrials.gov.
    • 25 Jan 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Jan 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top